Public discussions surrounding genetically modified foods and their impact on society and policy are often dominated by hyperbole and misinformation that hampers legitimate debate. To provide a clearer picture of the facts surrounding biotechnology and agriculture, ITIF presents a series of Points to Consider memos which analyze specific public statements surrounding GMOs, their accuracy and the implications for public policy.
Investment in Medical Innovation Produces Immense Value for Patients, Economies
The U.S. has already made great strides in the field of medical innovation. Maintaining our focus and investment in this field is a critical necessity in order for patients, economies and societies the world over to reap the benefits of future discoveries.
Reuters (Predictably) Gets It Wrong. Again
One of the reasons the “controversy” over crops improved through biotechnology persists, is because it is manufactured and sustained by a well-organized, ongoing campaign, funded and sustained by vested interests. This astroturf campaign is fueled by credulous and disengaged journalists who recycle their press releases, and allow those biases to bleed over into other coverage.
GMO Labeling is Unnecessary and Harmful to the Public Discourse
Professional biotech opponents are pushing in MD for legislation that would confuse and mislead consumers about genetically improved foods. ITIF looks at the science and finds the opponents claims to be abundantly contradicted by facts, data, and vast experience. The law would be very poor policy that would actually undermine the objectives it claims to want to advance.
Legislation Would Mandate Unfounded and Discriminatory Labels for Food
Biotech opponents in VT are pushing for a law to mandate misleading labels on genetically improved foods.The Senate Judiciary Committee is not keen on passing a law that would cost millions to defend in court against likely challenges. ITIF testimony demonstrates the claims of proponents are contradicted by science, data, and experience.
Legislation Banning Biotech Improved Grass is Bad for Consumers, Bad for Environment
Misguided opponents are pushing legislation in Connecticut that would ban a new biotech improved grass variety. The new grass would use less fertilizer, less water, require less mowing, and deliver improved weed management capabilities, reducing the enviornmental impact of lawns and golf courses. ITIF dissects the misguided objections of the opponents in testimony before the State Senate.
The Economic Benefits of Life Science Innovation
Innovation in life sciences has produced substantial health and economic benefits for countries worldwide. A new study measures the impact of new medicine and technology on Swedish health outcomes. The study provides a unique opportunity to see what would happen if intellectual property rights that encourage innovation were weakened.
The Potentially Deleterious Impacts of the President’s FY 2015 Budget on U.S. Life Sciences Industries
The President's FY 2015 budget request does not do enough to invest in innovation or to propose reforms to policies that hinder the competitiveness of key U.S. innovation industries. This is the case particularly with regard to three issues impacting U.S. life sciences industries: the budget's call for flat year-over-year funding for biomedical research at the National Institutes of Health (NIH), the budget’s call to provide only seven years of data exclusivity protection for novel biologic medicines, and the budget’s failure to repeal the self-destructive medical device tax that is contributing to the decimation of the U.S. medical device industry.